Iron Deficiency Anemia Market Insight
DelveInsight’s ‘Iron Deficiency Anemia (IDA) - Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the IDA, historical and forecasted epidemiology as well as the IDA market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The IDA market report provides emerging drugs, IDA market share of the individual cancer types, current and forecasted IDA market size from 2018 to 2030 segmented by seven major markets. The Report also covers current IDA market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2018–2030
Iron Deficiency Anemia
Iron Deficiency Anemia (IDA) Overview
Anemia is a condition that occurs when the quantity of red blood cells (RBCs) or hemoglobin concentration within them is lower than usual. Hemoglobin is required to transport oxygen, and if the patient has too few or malformed RBCs or not enough hemoglobin, the blood’s capacity to transport oxygen to the body’s tissues will be reduced.
Anemia is majorly characterized by a low number of RBCs and can cause weariness, shortness of breath, pallor, and weakness. RBC size, chronicity, and etiology are used to classify subtypes. Blood loss and decreased RBC production as observed in iron deficiency or increased RBC breakdown in hemolysis can all cause anemia. Iron deficiency has been estimated as the major cause of anemia.
The most common type of anemia is iron deficiency anemia (IDA), which happens when the body does not have enough iron. Iron is required to produce hemoglobin in the body. An insufficient amount of iron in the blood makes it difficult for oxygen to reach the entire body. Depending upon the amount of iron present, IDA can be classified into mild, moderate, and severe categories. Patients suffering from mild and moderate forms of the disease generally do not showcase any signs or symptoms. However, patients suffering from a severe form report symptoms like fatigue or tiredness, shortness of breath, or chest pain.
IDA is characterized by a lack of iron; this can be majorly due to low consumption of iron. Other causes of IDA include blood loss, the inability of the patient’s body to absorb iron, blood loss, any other comorbid condition, and others.
For IDA diagnosis, the doctor generally suggests a physical examination as well as recommends several blood tests. A complete blood count test is the preferred test to check the number of normal blood cells, iron, and the amount of ferritin present in the body.
Upon the diagnosis of IDA, the treatment begins. The treatment depends upon the patients’ characteristics and as well as the severity of the disease. Most of the patients are recommended iron supplements by doctors. These supplements can be either be oral (Auryxia, Accrufer and OTCs) or intravenous (Venofer, Monofer, Feraheme, and others). In extreme cases, patients have to undergo surgery or blood transfusion.
The IDA epidemiology division provides the insights about historical and current IDA patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted IDA epidemiology [segmented as Total prevalent cases of IDA, Total diagnosed prevalent cases of IDA, Total IDA cases by gender, Total IDA cases by pathology, Severity specific diagnosed cases of IDA, and Total Treated cases of IDA] scenario of IDA in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.
Country Wise- IDA Epidemiology
- In 2020, the total prevalent cases of IDA were 30,829,734 in the 7MM. The United States, in the same year, accounted for 9,313,895 cases. According to DelveInsight's analysis, Japan had the highest prevalence of IDA cases in the 7MM, accounting for approximately 39% of the total 7MM cases in 2020.
- IDA is often underdiagnosed and undertreated, as some people may not have any symptoms at first. In the EU-5 countries, the total diagnosed prevalent cases of IDA were 4,277,646 in 2020. Many programs have been launched in an attempt to minimize the prevalence of IDA in the Western world. Screening, health education, iron fortification of food, and increased usage of iron-rich baby formula are among them.
- Females are more likely to be afflicted by IDA than men. In 2020, the total IDA cases in women health were estimated around 2,060,787 in the 7MM. Among all the pathology related cause of IDA, IDA in chronic kidney disease have the highest patient pool in 2020.
- When a patient is diagnosed with IDA, an iron-rich diet and oral iron supplements can help treat the majority of mild-to-moderate IDA cases. In the 7MM, it is accessed that 9,266,923 cases received first-line oral therapies. Some of the patients who have received first-line oral treatments fail and move to second-line oral medications such as Feraccru (Accrufer) and Auryxia (Riona). Moreover, some proportion of patients who receive second-line oral treatments and who have severe IDA will proceed to IV iron therapy.
IDA Drug Chapters
Drug chapter segment of the IDA report encloses the detailed analysis of IDA marketed drugs and late stage (Phase-II) pipeline drugs. It also helps to understand the IDA clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
IDA Approved Drugs
Auryxia (Riona/ KRX-0502/Ferric Citrate): Akebia Therapeutics
Auryxia is an iron-based, non-calcium, non-chewable compound with distinctive chemical characteristics and a mechanism of action that render it dually effective as a therapy in patients with CKD. The active ingredient present in the drug is ferric citrate, a small molecule.
It was approved by the United States Food and Drug Administration (US FDA) in September 2014 as a phosphate binder for the Hyperphosphatemia indication and was commercially launched in the US shortly thereafter. In 2017, it received marketing approval from the FDA for a second indication, the IDA Indication for the treatment of adult patients, and was commercially launched for this indication in the United States.
Feraccru/Accrufer (Ferric Maltol/ ST10): Shield Therapeutics
Feraccru/Accrufer is a novel oral product that addresses the needs of patients who cannot tolerate existing oral iron products and offers a clear alternative to IV iron therapy. The drug is formulated as a capsule of ferric maltol containing 30mg iron, Ferric maltol is a tightly bound iron complex which does not dissociate so it is well tolerated and delivers the iron to the duodenum where the body absorbs iron naturally. Unabsorbed ferric maltol passes harmlessly through the digestive system as an unaltered complex and is excreted. Therefore, the drug offers a convenient, well tolerated and efficacious oral treatment alternative to IV iron therapy, without the need for hospital-based administration. The company’s lead product, Feraccru/Accrufer, has been approved for use in the US, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. In the European market the drug is marketed by the name of Feraccru.
Feraheme/Rienso (Ferumoxytol): AMAG Pharmaceuticals
Feraheme is an iron replacement product containing ferumoxytol for intravenous infusion. Ferumoxytol is a non-stoichiometric magnetite (superparamagnetic iron oxide) coated with polyglucose sorbitol carboxymethylether. The injection is a sterile aqueous colloidal product that is formulated with mannitol. It is a black to reddish brown liquid, and is provided in single-dose vials containing 510 mg of elemental iron. Feraheme received approval from the US FDA in June 2009 for use as an IV iron replacement therapy for the treatment of IDA in adult patients with CKD. Later on, the FDA expanded the label to include all eligible adult IDA patients.
Monofer (Iron Isomaltoside 1000/ Monoferric/ ferric derisomaltose/ NS-32): Pharmacosmos Therapeutics
Monoferric (ferric derisomaltose) is an intravenous iron replacement product, developed by Pharmacosmos Therapeutics. It is a complex of iron (III) hydroxide and derisomaltose, an iron carbohydrate oligosaccharide that releases iron. Iron binds to transferrin for transport to erythroid precursor cells to be incorporated into hemoglobin. The drug was approved in 30 countries outside of the US in 2009, later on in 2020 the US FDA granted approval to the drug for the treatment of IDA.
Ferinject/Injectafer (Ferric carboxymaltose/ VIT-45): Vifor Pharma
Ferinject (ferric carboxymaltose) is an intravenous (IV) iron indicated for the treatment of iron deficiency and IDA where oral iron is ineffective or cannot be used or when there is a clinical need to deliver iron rapidly. The active ingredient of the drug, ferric carboxymaltose, is composed of a poly-nuclear iron core stabilized by a carboxymaltose shell that ensures an effective iron utilization. When injected, this complex releases the iron, which will be either stored or exported in the blood plasma for transportation and utilization where it is needed. The drug developed by Vifor Pharma.
Venofer (Ferric Oxyhydroxide/Iron Sucrose): Vifor Pharma/American Regent
Venofer (iron sucrose (iron (III)-hydroxide sucrose complex) is a low-dose intravenous (IV) iron sucrose product, used for IV treatment of iron deficiency when oral iron preparations are ineffective or cannot be used e.g. in anemic dialysis patients. It is a nanomedicine, recognized by the US FDA. Scientific evidence demonstrates that nanomedicine similars have a different efficacy and safety profile compared with Venofer.
Note: Detailed Current therapies assessment will be provided in the full report of IDA
IDA Emerging Drugs
MPB-1514 (IOP Injection): MegaPro Biomedical
MPB-1514/ IOP Injection, developed by MegaPro Biomedical, is the non- sugar iron injection being developed for the treatment of IDA. It is highly secure as coated with PEG with good macrophage phagocytic results, high doses can be injected, which can effectively increase the number of red blood cells without frequent injections, providing greater convenience and compliance with doctor's orders for patients. As per the company, the drug is currently the only non-sugar injection iron being studied.
IDAX (IHAT-02): Nemysis
IHAT-02/ IDAX (Nemysis), is novel oral iron formulation, the first natural ferritin mimic, where a tartrate salt is used to “dope” the ferrihydrite nanocore of ferritin, in an adipate buffer. IHAT (Iron Hydroxide Adipate Tartrate) is well absorbed and preserves the gut microbiome. Absorption studies and early nutritional trials in human have shown that IHAT is absorbed efficiently and corrects markers of iron deficiency, without the burden of gastrointestinal side effects. The product is able to closely mimic normal iron absorption in the gut.
Note: Detailed emerging therapies assessment will be provided in the final report.
IDA Market Outlook
The IDA market size in the 7MM is expected to change during the forecast period (2021–2030), at a CAGR of 3.7%. According to the estimates, the highest market size of IDA is found in the United States.
The United States Market Outlook
In United States, the total market size of IDA is expected to increase at a CAGR of 4.2% during the study period (2018–2030).
EU-5 Countries: Market Outlook
In the EU-5 countries, the total market size of IDA is expected to increase at a CAGR of 1.2% during the study period (2018–2030).
Japan: Market Outlook
In the Japan, the total market size of IDA is expected to increase at a CAGR of 2.1% during the study period (2018–2030).
IDA Pipeline Development Activities
The drugs which are in pipeline include:
- MPB-1514: MegaPro Biomedical
- IDAX (IHAT-02): Nemysis
- Triferic: Rockwell Medical
Note: Detailed emerging therapies assessment will be provided in the final report.
IDA Drugs Uptake
In the early stages (mostly in mild to moderate IDA), patients are frequently prescribed with oral iron supplements, that comes in the form of tablets, pills, or syrups. There are numerous over-the-counter (OTC) oral iron treatments on the market. The adherence rate of the patients toward oral iron is low, as patients often face gastrointestinal side effects. If the patient has stopped responding to these medications or if their medication is no longer effectively working as it was used to, then in such cases, IV iron is suggested as the best option. But, IV iron often hamper the quality of life of patients and patients might have to visit the clinics for each administration. It is crucial to note that not all people can get IV irons in hospitals. When this issue is seen from the perspective of COVID-19, it gets much more problematic. According to DelveInsight's Market Research, the volume of oral iron products (including OTC and approved) is larger than that of IV iron treatments, although the sales produced by IV therapies are higher. In 2018, IV iron treatments accounted for almost 90% of the entire IDA market size in the 7MM. IV irons have been on the market for quite some time and are facing the danger of generics, but making IV iron knockoffs is extremely difficult. In a nutshell, there has been an urgent need for new therapeutic options for patients who do not require IV iron and hospitalization for quite some time.
Access and Reimbursement Scenario in IDA
Auryxia, is an oral drug, is covered by Medicare only under Part D. The company have gained broad access for Auryxia in the United States in both Medicare Part D and commercial channels. It is currently covered for the Hyperphosphatemia Indication in nine of the ten largest Medicare Part D plans. In September 2018, the Centers for Medicare & Medicaid Services, or CMS, decided that Auryxia would no longer be covered by Medicare for the IDA Indication. While this decision does not impact CMS coverage of the Hyperphosphatemia Indication, it requires all Auryxia prescriptions for Medicare patients to undergo a prior authorization to ensure their use in the Hyperphosphatemia Indication. In October, 2019, the company filed a complaint in the United States District Court for the District of Massachusetts against CMS and the US.
To keep up with current market trends, we take KOLs and SME’s opinion working in IDA domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or IDA market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the IDA Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of IDA, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
- Comprehensive insight has been provided into the IDA epidemiology and treatment in the 7MM.
- Additionally, an all-inclusive account of both the current and emerging therapies for IDA is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of IDA market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global IDA market.
- In the coming years, IDA market is set to change due to the entry of new oral iron supplements having fewer side effects, an increase in the number of IDA patients mainly due to general lifestyle changes and also due to risk factors like malaria are some of the major factors expected to contribute in the growth of the IDA market.
- The companies and academics are working to assess challenges and seek opportunities that could influence IDA R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for IDA. Launch of emerging therapies, will significantly impact the IDA market.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
IDA Report Insights
- Patient Population
- Therapeutic Approaches
- IDA Pipeline Analysis
- IDA Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
IDA Report Key Strengths
- 10 Years Forecast
- 7MM Coverage
- IDA Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
IDA Report Assessment
- SWOT Analysis
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- What was the IDA Market share (%) distribution in 2018 and how it would look like in 2030?
- What would be the IDA total market size as well as market size by therapies across the 7MM during the study period (2018–2030)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest IDA market size during the study period (2018–2030)?
- At what CAGR, the IDA market is expected to grow in the 7MM during the study period (2018–2030)?
- What would be the IDA market outlook across the 7MM during the study period (2018–2030)?
- What would be the IDA market growth till 2030 and what will be the resultant market size in the year 2030?
- How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
- IDA patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
- How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies on the basis of their clinical trial results?
- Among the emerging therapies, what are the potential therapies which are expected to disrupt the IDA market?
- What is the challenges and unmet needs of the IDA?
- What is the historical IDA patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
- What would be the forecasted patient pool of IDA in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to IDA?
- Out of all the 7MM countries, which country would have the highest prevalent population of IDA during the study period (2018–2030)?
- At what CAGR the population is expected to grow in the 7MM during the study period (2018–2030)?
- What are the various recent and upcoming events which are expected to improve the uptake of IDA?
Current Treatment Scenario and Emerging Therapies:
- What are the current treatment guidelines for the treatment of IDA in the US, Europe and Japan?
- How many companies are developing drugs for IDA?
- How many drugs for IDA are developed by each company?
- How many emerging therapies are in mid stage, and late stage of development?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the IDA?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for IDA and their status?
- What are the key designations that have been granted for the emerging therapies for IDA?
- What is the global historical and forecasted market of IDA?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the IDA market.
- To understand the future market competition in the IDA market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for IDA in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
- Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for IDA market.
- To understand the future market competition in the IDA market.
1. Key Insights
2. Report Introduction
3. Iron deficiency Anemia Market Overview at a Glance: By Country
3.1. Market Share (%) Distribution of Iron deficiency Anemia in 2018
3.2. Market Share (%) Distribution of Iron deficiency Anemia in 2030
4. Iron deficiency Anemia Market Overview at a Glance: Oral vs. IV Iron by Sales
4.1. Market Share (%) Distribution of Iron deficiency Anemia in 2018
4.2. Market Share (%) Distribution of Iron deficiency Anemia in 2030
5. Executive Summary of Iron deficiency Anemia
5.1. Key Events
6. Epidemiology and Market Forecast Flow
7. Background and Overview
7.2.1. Types of Anemia
7.3. Iron deficiency Anemia
7.4. Signs and Symptoms of IDA
7.5. Causes of IDA
7.6. Risk factors of IDA
7.7. Pathophysiology of IDA
7.7.1. Iron Cycle
7.7.2. Stages of Iron Deficiency
7.8. Diagnosis of IDA
7.8.1. Differential Diagnosis
7.8.2. Diagnostic Algorithm of IDA
7.8.3. Academy of Family Physicians (AAFP) Guidelines for the Diagnosis of IDA
7.8.4. British Society of Gastroenterology Guidelines for the Diagnosis of IDA in Gastrointestinal (GI) Diseases
7.8.5. UK National Screening Committee (NSC) Screening Recommendation
8.1. Algorithm for the Treatment of IDA
8.2. Guidelines for the treatment of IDA
8.2.1. Treatment of IDA During Pregnancy
8.2.2. British Society of Gastroenterology Guidelines on the Treatment of IDA
8.2.3. WHO Guideline: Use of Ferritin Concentrations to Assess Iron Status in Individuals and Populations
8.2.4. WHO Guideline: Daily Iron Supplementation in Adult Women and Adolescent Girls
8.2.5. Guidelines on Prevention and Treatment of IDA in Infants and Young Children
8.2.6. European Society for Medical Oncology (ESMO) Guidelines for the Management of Anemia and Iron Deficiency in Patients with Cancer
8.2.7. European Crohn’s and Colitis Organization Guidelines for IDA
9. Epidemiology and Patient Population
9.1. Key Findings
9.2. Assumptions and Rationale
9.3. Epidemiology Scenario (7MM)
9.3.1. Total prevalent cases of Iron Deficiency Anemia (IDA) in the 7MM
9.3.2. Total diagnosed prevalent cases of Iron Deficiency Anemia (IDA) in the 7MM
9.3.3. Total Iron Deficiency Anemia (IDA) cases by gender in the 7MM
9.3.4. Total Iron Deficiency Anemia (IDA) cases by pathology in the 7MM
9.3.5. Severity-Specific Diagnosed cases of IDA in the 7MM
9.3.6. Total treated cases of Iron Deficiency Anemia (IDA) in the 7MM
10. Patient Journey
11. Key Endpoints for Iron deficiency Anemia
12. Marketed Therapies
12.1. Key Cross of Marketed Therapies
12.2. Auryxia (Riona/ KRX-0502/Ferric Citrate): Akebia Therapeutics
12.2.1. Product Description
12.2.2. Regulatory Milestones
12.2.3. Other Developmental Activities
12.2.4. Pivotal Clinical Trial
12.2.5. Ongoing Current Pipeline Activity
12.3. Feraccru/Accrufer (Ferric Maltol/ ST10): Shield Therapeutics
12.3.1. Product Description
12.3.2. Regulatory Milestones
12.3.3. Other Developmental Activities
12.3.4. Pivotal Clinical Trial
12.4. Feraheme/Rienso (Ferumoxytol): AMAG Pharmaceuticals
12.4.1. Product Description
12.4.2. Regulatory Milestones
12.4.3. Other Developmental Activities
12.4.4. Pivotal Clinical Trial
12.4.5. Ongoing Current Pipeline Activity
12.5. Monofer (Iron Isomaltoside 1000/ Monoferric/ ferric derisomaltose/ NS-32): Pharmacosmos Therapeutics
12.5.1. Product Description
12.5.2. Regulatory Milestones
12.5.3. Other Developmental Activities
12.5.4. Pivotal Clinical Trial
12.6. Ferinject/Injectafer (Ferric carboxymaltose/ VIT-45): Vifor Pharma
12.6.1. Product Description
12.6.2. Regulatory Milestones
12.6.3. Other Developmental Activities
12.6.4. Pivotal Clinical Trial
12.6.5. Ongoing Current Pipeline Activity
12.7. Venofer (Ferric Oxyhydroxide/Iron Sucrose): Vifor Pharma/American Regent
12.7.1. Product Description
12.7.2. Regulatory Milestones
12.7.3. Other Developmental Activities
12.7.4. Pivotal Clinical Trial
13. Emerging Therapies
13.1. Key Cross of Emerging Therapies
13.2. MPB-1514 (IOP Injection): MegaPro Biomedical
13.2.1. Product Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.3. IDAX (IHAT-02): Nemysis
13.3.1. Product Description
13.3.2. Other Developmental Activities
14. Prescription or Over the Counter Drugs (Rx/OTC)
15. Non Drug Iron Supplements
16. Iron deficiency Anemia: 7 Major Market Analysis
16.1. Key Findings
16.2. Market Outlook
16.3. Market Size of IDA
16.3.1. Total Market Size of IDA
16.3.2. Market Size of IDA by Therapies
17. Market Access and Reimbursement
17.1. Centers for Medicare & Medicaid Services, or CMS: The United States
17.2. United Healthcare Commercial Medical Benefit DrugPolicy
17.3. Northern (NHS) Treatment Advisory Group (NTAG): The United Kingdom
17.4. Haute Autorité de santé (HAS): France
17.5. Patient Assistance Programs
18. Market Drivers
19. Market Barriers
20. SWOT Analysis
21. Unmet Needs
22.2. Report Methodology
23. DelveInsight Capabilities
25. About DelveInsight
List of Table
Table 1: Summary of IDA: Market, Epidemiology, and Key Events (2018–2030)
Table 2: Severity of Anemia in Different Age Groups, Sex, and Pregnancy Status by level of hemoglobin (g/dL)
Table 3: Differential Diagnosis of IDA
Table 4: Iron Therapy: Formulations and Dosing
Table 5: Comparison of oral versus intravenous iron therapy
Table 6: Suggested Scheme for Daily Iron Supplementation in Adult Women and Adolescent Girls
Table 7: Total prevalent cases of Iron Deficiency anemia (IDA) in the 7MM (2018–2030)
Table 8: Total diagnosed prevalent cases of Iron Deficiency anemia (IDA) in the 7MM (2018–2030)
Table 9: Total Iron Deficiency anemia (IDA) cases by gender in the 7MM (2018–2030)
Table 10: Total Iron Deficiency anemia (IDA) cases by pathology in the 7MM (2018–2030)
Table 11: Severity-Specific Diagnosed prevalent cases of IDA in the 7MM (2018–2030)
Table 12: Total treated cases of Iron Deficiency Anemia (IDA) in the 7MM
Table 13: Auryxia (Riona/ KRX-0502/Ferric Citrate), Clinical Trial Description, 2021
Table 14: Feraheme (ferumoxytol injection), Clinical Trial Description, 2021
Table 15: Injectafer (Ferinject/ ferric carboxymaltose/ VIT-45), Clinical Trial Description, 2021
Table 16: MPB-1514; Clinical Trial Description, 2021
Table 17: 7MM Market Size of IDA in USD Million (2018–2030)
Table 18: 7MM Market Size of IDA in USD Million (2018–2030)
Table 19: The United States Market Size of IDA in USD Million (2018–2030)
Table 20: EU-5 Market Size of IDA by Therapies in USD Million (2018–2030)
Table 21: Japan Market Size of IDA by Therapies in USD Million (2018–2030)
Table 22: HAS France assessment for IDA drugs
List of Figures
Figure 1: Classification of Anemia
Figure 2: Signs and Symptoms of IDA
Figure 3: Risk Factors of IDA
Figure 4: Iron Circuit in the Human Body
Figure 5: Differential Diagnosis of IDA
Figure 6: Diagnostic Algorithm for IDA
Figure 7: Treatment Algorithm for IDA (Gastrointestinal)
Figure 8: Treatment Algorithm for IDA
Figure 9: Total prevalent cases of Iron Deficiency anemia (IDA) in the 7MM
Figure 10: Total diagnosed prevalent cases of Iron Deficiency anemia (IDA) in the 7MM (2018–2030)
Figure 11: Total Iron Deficiency Anemia (IDA) cases by gender in the 7MM (2018–2030)
Figure 12: Total Iron Deficiency anemia (IDA) cases by pathology in the 7MM (2018–2030)
Figure 13: Severity-Specific Diagnosed prevalent cases of Iron Deficiency anemia (IDA) in the 7MM
Figure 14: Total treated cases of Iron Deficiency Anemia (IDA) in the 7MM
Figure 15: Market Size of IDA in the 7MM, USD Million (2018–2030)
Figure 16: 7MM Market Size of IDA in USD Million (2018–2030)
Vifor Pharma/American Regent